Nubeqa+Taxotere+ADT prolongs survival vs Taxotere+ADT in newly-diagnosed metastatic patients.

[Tall_Allen]

This was just announced in a press release about preliminary results of the ARASENS trial:

businesswire.com/news/home/...

I don't know how long it extends survival for - they will announce that at an upcoming conference.

This is being called "triplet therapy" = (1) a second generation hormonal + (2) ADT (e.g. Lupron) +(3) Chemo (e.g., Taxotere/docetaxel)

The other second-generation hormonal therapy that recently was found to extend survival as part of a triplet was abiraterone (Zytiga) in the PEACE1 trial:

prostatecancer.news/2021/05...

For some unknown reason, enzalutamide (Xtandi) didn't work as a triplet.

[lincolnj8]

Thanks, great information

[Ahk1]

Thanks TA for posting this important info

[PGDuan]

Thanks for highlighting this Allen. Would think the insights applies to those who are micrometastic / BCR?

As someone BCR after primary therapy (but still low PSA), I'm trying to decide what to do and when.

The "triplet" seems to provide the best outcomes for the group studied, butI presume chemo was generally added given distant / multiple metastases. The adverse reactions and side effects seem notable too.

[Tall_Allen in reply to PGDuan]

Idk if it applies to those whose metastases only show up on PET scans or if they are recurrent - it does only apply to those who have not been on medication, although temporary adjuvant ADT is probably OK - but I'm just guessing.